• Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium
  • Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
  • Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy

Company

Unternehmen
Fresenius Biotech develops and markets biopharma-ceuticals for the effective treatment of severe diseases. ... more

Transplantation

Labormitarbeiter
ATG Fresenius® S, a polyclonal antibody, is successfully marketed in over 60 countries. ... more

Oncology

We develop and market innovative antibody therapies for the treatment of cancer. We recently launched Removab®, a trifunctional antibody indicated for the treatment of malignant ascites. ... more